MedTrace Logo

Efficacy and Safety of Prepopik® in Children for Overall Colon Cleansing in Preparation for Colonoscopy

NCT01928862 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 78

Last updated 2018-04-23

Study results available
· View outcomes & findings →

Summary

To study the efficacy and safety of Prepopik® in children aged 9 to 16 years for overall colon cleansing in preparation of colonoscopy

Conditions

  • Need for Bowel Preparation

Interventions

DRUG

Prepopik® ½ Sachet x 2 (9-12 years)

DRUG

Prepopik® 1 Sachet x 2 (9-12 years)

DRUG

Oral polyethylene glycol (PEG) based preparation (9-12 years)

DRUG

Prepopik® 1 Sachet x 2 (13-16 years)

DRUG

Oral polyethylene glycol (PEG) based preparation (13-16 years)

Sponsors & Collaborators

  • Ferring Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Clinical Development Support · Ferring Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
9 Years
Max Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-06-03
Primary Completion
2017-02-15
Completion
2017-03-16

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01928862 on ClinicalTrials.gov